Literature DB >> 20715157

The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors.

Christina Justenhoven1, Stefan Winter, Ute Hamann, Susanne Haas, Hans-Peter Fischer, Beate Pesch, Thomas Brüning, Yon-Dschun Ko, Hiltrud Brauch.   

Abstract

BACKGROUND: CYP3A enzymes, due to their role in the metabolism of steroid hormones, are suggested to affect carcinogenesis of hormone-related cancers. The purpose of the present study was to evaluate the association between polymorphisms located in CYP3A43, breast cancer risk, and tumor characteristics.
METHODS: A 3-plex matrix-assisted laser desorption ionization time of flight mass spectrometry assay has been established for CYP3A43_74_delA (CYP3A43*2A), CYP3A43_1018_C>G (CYP3A43*3), and CYP3A43_1047_C>T (CYP3A43*1B) polymorphisms, and 1021 breast cancer cases and 1015 age-matched, population-based controls from the German GENICA collection have been genotyped.
RESULTS: No differences in genotype frequencies between cases and controls were observed, indicating that CYP3A43_74_delA is not associated with breast cancer risk. Subgroup analyses showed an association between the CYP3A43_74_delA allele and high-grade tumors (odds ratio, 1.74; 95% confidence interval, 1.14-2.65 [P=.010 and Ptrend=.012]).
CONCLUSIONS: The data support the notion that the CYP3A43_74_delA variant may result in decreased protein and/or activity levels, and this may further lead to increased hormone levels to promote tumor cell growth and hinder differentiation.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20715157     DOI: 10.1002/cncr.25508

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.

Authors:  Ningning Dong; Jing Yu; Chaoying Wang; Xiaohui Zheng; Zheng Wang; Lijun Di; Guohong Song; Budong Zhu; Li Che; Jun Jia; Hanfang Jiang; Xinna Zhou; Xiaoli Wang; Jun Ren
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-17       Impact factor: 4.553

Review 2.  Genetic variation in CYP3A43 is associated with response to antipsychotic medication.

Authors:  Eva J Brandl; Nabilah I Chowdhury; Arun K Tiwari; Tristram A P Lett; Herbert Y Meltzer; James L Kennedy; Daniel J Müller
Journal:  J Neural Transm (Vienna)       Date:  2014-08-24       Impact factor: 3.575

3.  The UGT1A6_19_GG genotype is a breast cancer risk factor.

Authors:  Christina Justenhoven; Ofure Obazee; Stefan Winter; Sylvia Rabstein; Anne Lotz; Volker Harth; Beate Pesch; Thomas Brüning; Christian Baisch; Jaana M Hartikainen; Arto Mannermaa; Veli-Matti Kosma; Vesa Kataja; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Peter A Fasching; Matthias Beckmann; Arif B Ekici; Alexander Hein; Per Hall; Jingmei Li; Jenny Chang-Claude; Dieter Flesch-Janys; Petra Seibold; Anja Rudolph; Ute Hamann; Yon-Dschun Ko; Hiltrud Brauch
Journal:  Front Genet       Date:  2013-06-11       Impact factor: 4.599

4.  Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk.

Authors:  Christina Justenhoven
Journal:  Front Genet       Date:  2012-11-28       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.